Abstract Blood brain barrier (BBB) disruption is an important contributor to brain edema and neurological deficits following intracerebral hemorrhage (ICH). Macrophage stimulating protein (MSP) is a hepatocyte growth factor-like protein that mediates its functions via activating receptor tyrosine kinase recepteur d'origine nantais (RON). Grb2-associated binder 1 (GAB1) is a docking protein that mediates downstream receptor signal transduction pathways. This study aimed to evaluate the role of MSP and RON activated signaling pathway in preserving BBB integrity after collagenase-induced ICH. ICH mice received recombinant human MSP (rhMSP) or rhMSP combined with siRNA knockdown of RON or GAB1. rhMSP was administered by intranasal route 1 h after ICH. Brain edema, neurobehavior, BBB tight junction protein expression, and BBB permeability were evaluated. The expression of endogenous MSP and p-RON was decreased after ICH. Exogenous rhMSP administration reduced brain edema, neurological deficits, BBB permeability, and increased the expression of tight junction proteins in ICH mice. rhMSP administration increased the expression of p-RON, p-GAB1, p-Src, nuclear b-catenin, and tight junction proteins after ICH. These effects were reversed with RON and GAB1 siRNA. We conclude that MSP activation of RON preserved BBB integrity via GAB-1/Src/b-catenin pathway, thereby reducing brain edema and neurological deficits after ICH in mice. Keywords: b-catenin, blood brain barrier, intracerebral hemorrhage, macrophage stimulating protein, recepteur d'origine nantais.
Spontaneous intracerebral hemorrhage (ICH) is the second most common sub-type of stroke with high morbidity and mortality rates among all types of stroke (Keep et al. 2012) . ICH occurs when cerebral blood vessel integrity is breached and leaks into the brain parenchyma. ICH accounts for approximately 10%-15% of all strokes worldwide each year (Qureshi et al. 2009; Kuramatsu et al. 2013) . The incidence of ICH is increasing and is expected to double by the year 2050 (Qureshi et al. 2001; Kuramatsu et al. 2013) . Clinical trials and preclinical studies indicate that ICH afflicted patients often suffer from devastating functional outcomes and high mortality. Surgical intervention and medical management of ICH patients are primarily used in clinical practice but do not always benefit patients (Dey et al. 2014) .
Blood brain barrier (BBB) disruption is one of the major consequences of ICH induced brain injury that contributes to perihematomal cerebral edema formation. The disintegration of endothelial tight junctions promotes capillary leakage resulting in mass effect by the extravasated fluid which contributes to neurological deterioration (Gebel et al. 2002) . The disruption of BBB also promotes peripheral leukocyte influx into the perihematomal area that release inflammatory cytokines which further aggravates brain edema (Keep et al. 2008) . Therefore, treatment strategy to enhance BBB integrity may provide therapeutic potential for ICH.
Macrophage-stimulating protein (MSP) is a kind of heterodimeric protein that has 45% similar sequence with hepatocyte growth factor-like protein (HGF) (Han et al. 1991; Yoshimura et al. 1993) . MSP has also been shown to play a role in inducing adhesion and motility of epithelial cells and attenuating apoptosis (Danilkovitch and Leonard 1999) . MSP regulates its biological activities by binding to and activating its specific tyrosine kinase receptor, recepteur d'origine nantais (RON) (Gaudino et al. 1994; Wang et al. 1994) . RON, a member of cmet proto-oncogene family, is a type of transmembrane tyrosine kinase receptor. MSP induces RON dimerization and autophosphorylation, which activates downstream signaling pathways (Gaudino et al. 1994) . Grb2-associated binder 1 (GAB1) is a docking protein that was shown to mediate the signaling pathways of MSP-related HGF in a mouse model of hind limb ischemia (Shioyama et al. 2011) .
We speculated that MSP activation of RON may protect the BBB integrity after ICH. The potential endothelial protective function of MSP and RON in brain hemorrhage has not been previously studied. Furthermore, the mechanism by which MSP and RON protect the endothelial barrier is not known. In this study, we investigated if exogenous recombinant human MSP (rhMSP) administration enhances BBB integrity through RON activation of GAB1/Src/b-catenin pathway in an ICH mouse model.
Materials and methods

Animals and surgeries
All the animal experiments for this study were approved by the Loma Linda University Institutional Animal Care and Use Committee. The ethical approval reference number is IACUC 8150020. The study was not pre-registered. A total of two hundred and twenty-two 8-week male CD1 mice [30 AE 5 g, Crl:CD1(ICR) 022; Charles River, Wilmington, MA, USA] were used in this study. Animals were housed in a 12-h light/dark cycle at a temperaturecontrolled environment and fed ad libitum. ICH was induced by stereotactic-guided injection of bacterial collagenase into the right basal ganglia, as previously described (Krafft et al. 2013) . Briefly, the mice were intraperitoneally injected with ketamine (100 mg/kg, K2573; Sigma-Aldrich, St. Louis, MO, USA) and xylazine (10 mg/ kg, X1126; Sigma-Aldrich) to be anesthetized. Bacterial collagenase (0.075 units, Type VII-S, C2399; Sigma-Aldrich) was dissolved in 0.5 lL saline. The collagenase solution was injected into the right basal ganglia (coordinates 0.2 mm anterior, 3.5 mm ventral, and 2.2 mm lateral to the bregma) at a rate of 0.1667 lL/min by a micro infusion pump (Harvard Apparatus Inc., South Natick, MA, USA). The needle was left in the position for additional 5 min to prevent reflux and withdrawn slowly. The cranial hole was filled with bone wax and the skin was closed with suture. Animals were allowed to recover completely under observation. Sham-operated mice received only the needle insertion but without collagenase injection.
Mice were anesthetized during all surgical and sample collection procedures. Depth of anesthesia was checked by toe-pinch response to pain. To provide post-procedural pain relief, buprenorphine (0.03 mg/kg, B9275; Sigma-Aldrich) was administered subcutaneously. If animals exhibited distress, the dose was increased to once daily for 3 days or twice per day. To minimize animal discomfort, during ICH surgery, we moistened the mice eyes with ophthalmic lubricant to prevent them from drying. Also, the mice were placed onto the heating pad to maintain body temperature. In addition, saline was injected subcutaneously into the flanks of the hind limbs to avoid post-surgical dehydration.
All mice were euthanized according to the recommended AVMA guidelines on euthanasia. Under deep isoflurane anesthesia (checked by a negative response to painful stimuli) cervical dislocation was performed before decapitation and sample collection.
Animal treatments and experimental groups
We used pseudo randomization to assign all mice to each group and all investigators were blinded. All animals will be pseudo randomly assigned into various experimental groups by generating random numbers using Excel that will be assigned to each animal and groups (Kim and Shin 2014) . Eight-week male CD1 mice were pseudo randomly assigned to the following groups: Sham, ICH + Vehicle, ICH + rhMSP (MSP-0.1 lg), ICH + rhMSP (MSP-0.3 lg), ICH + rhMSP (MSP-1 lg), ICH + rhMSP + scrambled siRNA, ICH + rhMSP + RON siRNA, ICH + rhMSP + GAB1 siRNA. rhMSP (6244-MS-025/CF; R&D Systems, Minneapolis, MN, USA) was administered via intranasal route 1 h post-ICH and then once daily for 3 days to the 72 h groups. The scrambled siRNA (100 pmol/lL, 2 lL, SR30004; OriGene, Rockville, MD, USA), RON siRNA (100 pmol/lL, 2 lL, SR422760; OriGene), and GAB1 siRNA (100 pmol/lL, 2 lL, SR419225; OriGene) were administered via intracerebroventricular injection 24 h before ICH induction (Fig. 1) .
Short-term neurobehavioral analysis
Short-term neurological deficits were evaluated using modified Garcia test, corner turn test and limb placement at 24 and 72 h after ICH surgery as previously described (Tong et al. 2017) . Garcia test was performed according to a 21-point score system with seven individual tests that included spontaneous activity, side stroke, vibrissae touch, limb symmetry, lateral turning, forelimb walking, and climbing. In the corner turn test, mice were allowed to enter into a 30°angle corner. The animals exit the corner with either right or left turn. The percent of left turns in 10 trials were calculated. In the forelimb placement test, the placement of the ipsilateral forelimb on the countertop when the vibrissa was stimulated was recorded. The percent of ipsilateral forelimb placement of ten total trials was calculated.
Long-term neurological evaluation
In the long-term neurological study, we chose the Morris water maze to test spatial learning capacity and memory function recovery as previously described (Lekic et al. 2010) . The water maze is a round metal reservoir filled with water which is painted black. We put a platform in the center of the quadrants. In this test, animals needed to find an underwater platform. We used an overhead camera to record the whole process. In order to test the spatial learning capacity and memory function recovery, we placed animals at the starting locations of semi random. Each mouse is limited to find the platform in 60 s. After that, the mice were guided to the platform and stayed for 5 s. The probe trial was carried out at the last day. We removed the actual platform and let the mice to search the preexistent platform area. A computerized tracking system (Noldus Ethovision; Noldus, Tacoma, WA, USA). was used to record the escape latency, swimming path, and swimming distance.
Brain water content measurement
Mice were anesthetized with isoflurane and then sacrificed at 24 or 72 h post ICH as we have previously described. Brain tissue was removed and collected at 24 or 72 h after ICH to measure brain water content as previously described (Tong et al. 2017) . The samples were separated into ipsilateral basal ganglia (ispi-BG), contralateral basal ganglia, ipsilateral cortex (ispi-CX), contralateral cortex, and cerebellum, then weight (wet weight) immediately. After drying in 100°C for 72 h (dry weight), the percentage of brain water content was calculated using the following formula: [(wet weight À dry weight)/wet weight] 9 100%.
Evaluation of BBB permeability and hematoma volume assessment Evans blue dye extravasation assay was performed to evaluate BBB permeability as previously described (Ma et al. 2011) . Briefly, after mice were anesthetized with isoflurane at 24 h post ICH, mice were transcardially perfused with 60 mL ice cold phosphate buffered saline (PBS) (pH 7.4). Mice were sacrificed at 24 h after ICH as we have previously described. 4% evans blue dye (0.25 mL, E2129; SigmaAldrich) was injected via intraperitoneal route 3 h before sacrifice. Brain tissues were quickly removed after perfusion with ice-cold PBS (50 mL, P5368; Sigma-Aldrich) then separated into right and left hemisphere. All samples were snap-frozen in liquid nitrogen and stored at À80°C. The right hemisphere was homogenized with 1100 lL PBS, and then sonicated. Tissues samples were centrifuged for 30 min at 15 000 g. Next, 500 lL supernatant from each sample was incubated with 500 lL trichloroacetic acid (50%) overnight at 4°C. The samples were then centrifuged 30 min at 15 000 g. The quantity of Evans blue dye extravasation was evaluated spectrophotometrically at a wavelength of 610 nm and quantified according to a standard curve. Then, hematoma volume was evaluated using hemoglobin assay (Ma et al. 2011) . After homogenizing ipsilateral hemispheres for 60 s in 3 mL distilled water, the homogenized specimens were centrifuged for 30 min at 12 000 g. Next, 80 lL Drabkin's reagent (D5941; Sigma-Aldrich) was added to 20 lL supernatant obtained from the brain samples and allowed to incubate for 15 min. A standard curve was used to measure hemoglobin absorbance at 540 nm using a spectrophotometer.
Western blot analysis
Mice were anesthetized with isoflurane at 24 h post ICH, and transcardially perfused with 60 mL ice cold PBS (pH 7.4). Western blot analysis was performed as previously described (He et al. 2015) . Nuclear and cytoplasmic fractions were extracted by NE-PER nuclear and cytoplasmic extraction reagents (78835; Thermofisher Scientific, Waltham, CA, USA) following the instruction manual. The lysates from brain tissues were separated by 10% SDS-PAGE and transferred onto nitrocellulose membranes. After blocking with 5% non-fat blocking milk (Bio-Rad, CA, #1706404XTU) in Tris-buffered saline (#1706435; Bio-Rad, Hercules, CA, USA) with 0.1% Tween 20 (#1706531; Bio-Rad) dissolved in double distilled water, the membranes were incubated with the following primary antibodies including MSP [1 : 1000, research resource identifiers (RRID): AB_10976147; Abcam, Cambridge, MA, USA], phospho-RON (1 : 500, RRID: AB_669916; Santa Cruz Biotechnology, Santa Cruz, TX, USA), RON (1 : 1000, RRID: AB_10972503; Abcam), phospho-GAB1 (1 : 500, RRID: AB_653233; Santa Cruz Biotechnology), GAB1 (1 : 1000, RRID: AB_107088588; Santa Cruz Biotechnology), phospho-Src (1 : 1000, RRID: AB_776106; Abcam), Src (1 : 1000, RRID: AB_10865528; Abcam), b-catenin (1 : 1000, RRID: AB_725966; Abcam), claudin-5 (1 : 1000, RRID: AB_2260866; Santa Cruz Biotechnology), occludin (1 : 1000, RRID: AB_2156317; Santa Cruz Biotechnology), ZO-1 (1 : 1000, RRID: AB_628459; Santa Cruz Biotechnology), actin (1 : 1000, RRID: AB_2223345; Santa Cruz Biotechnology), Albumin (1 : 1000, RRID: AB_2225785; Cell signaling Technology, Beverly, MA, USA), lamin-B (1 : 1000, RRID: AB_2616597; Abcam) at 4°C overnight. The next day, after being washed with washing buffer (Tris-buffered saline with 0.1% Tween 20 dissolved in double distilled water), the membranes were incubated with appropriate secondary antibodies (RRID: AB_631746 or AB_631728; Santa Cruz Biotechnology). Bands were visualized using the ECL Plus chemiluminescence kit (RPN3243; Amersham Bioscience, Bensenville, IL, USA). Image J (4.0, Media Cybernetics, Rockville, MD, USA) was used for semi-quantitative analysis of the bands. Results were presented as relative density ratio to actin or lamin-B, normalized to the mean values of the sham group.
Immunohistochemistry staining Briefly, after being anesthetized with isoflurane and intracardially perfused with PBS and 10% formalin, brains were removed, fixed in 10% formalin overnight, immersed in 30% sucrose for 3 d, and then frozen. Fixed frozen brain tissues were sectioned at 10 lm by using cryostat (Leica CM3050S-3-1-1, Wetzlar, Germany). Double immunofluorescence staining was performed as previously reported (He et al. 2015) . Sections were permeabilized with 0.3% Triton X-100 for 30 min. After blocking with 5% donkey serum for 1 h, the sections were incubated with the following primary antibodies: anti-MSP (1 : 1000, RRID: AB_10976147; Abcam), anti-RON (1 : 1000, RRID: AB_10972503; Abcam), anti-GFAP (1 : 1000, RRID: AB_627673; Santa Cruz Biotechnology), anti-vWF (1 : 500, RRID: AB_10842026; Santa Cruz Biotechnology), and anti-NeuN (1 : 500, RRID: AB_2532109; Abcam), at 4°C overnight, followed by appropriate fluorescence-conjugated secondary antibodies (RRID: AB_2337972, AB_2338059, AB_2340432 or AB_2338871; Jackson Immuno-Research Laboratories, West Grove, PA, USA) at 25°C for 2 h. The co-localizations were evaluated by a fluorescent microscope (Olympus OX51, Tokyo, Japan).
Statistical analysis
To reduce experimenter bias and achieve unbiased results, the investigators performing the neurological tests and molecular experiments (brain water content, hematoma volume, Evans blue dye extravasation and western blot) were blinded to animal groups and the interventions that animals received. Sample size was not predetermined by formal power statistical methods. There were no sample size differences between the beginning and end of the experiments. Samples were excluded when mice died from anesthesia or ICH surgery. Samples size were estimated using a type I error rate of 0.05 and a power of 0.8 on a two-sided test by power analysis. The sample number of each experiment is presented in the figures. Data were expressed as mean AE SD or median with range and data were analyzed using GraphPad Prism 6 software (La Jolla, CA, USA). All data were tested for normality using Shapiro-Wilk test to make sure that they were normally distributed before ANOVA analysis. No tests were performed for outliers and no data was excluded from the analysis. Parametric data was analyzed using one-way ANOVA followed by the Tukey's post hoc test. Non-parametric data was analyzed by KruskalWallis with Dunn's post hoc tests. p values < 0.05 was considered statistically significant.
Results
ICH suppressed the endogenous expression of MSP and p-RON Double immunofluorescence staining was performed to determine the cellular localization of MSP and RON 24 h after ICH. MSP and RON immunoreactivity was mostly observed in the astrocytes and endothelial cells while less expression was visualized in the neurons at the perihematomal area 24 h after ICH (Fig. 2a and b respectively) .
Western blot was performed to measure the endogenous expression of MSP, p-RON, and RON at 3, 6, 12, 24, 72 h after ICH. The expression of endogenous MSP was significantly reduced starting at 6 h after ICH up to 72 h compared to sham (Fig. 2c and d) . Phosphorylated RON (p-RON) expression was significantly reduced at all time points after ICH from 3 h up to 72 h compared to sham (Fig. 2c and e) . rhMSP treatment decreased brain edema and ameliorated ICH induced neurological deficits 24 h and 72 h after ICH Brain water content was significantly increased in the ispi-BG and ispi-CX at 24 h (Fig. 3a) . Three different dosages of rhMSP (0.1, 0.3, and 1 lg) were administered through intranasal 1 h after ICH. It was found that the brain water content in both ispi-BG and ispi-CX was significantly reduced in the rhMSP (0.3 lg) treatment group compared to vehicle group 24 h after ICH (Fig. 3a) . rhMSP (0.3 lg) treatment also significantly improved neurological outcomes in modified Garcia test (Fig. 3b , Figure  S1 ) and limb placement (Fig. 3d ) at 24 h after ICH. In the corner turn test (Fig. 3c) , rhMSP treatment showed a trend toward improvement but did not reach statistical significance. Thus, rhMSP (0.3 lg) was selected to evaluate outcomes at 72 h and to elucidate rhMSP's mechanism of action.
The brain water content in both ispi-BG and ispi-CX was significantly reduced in the rhMSP (0.3 lg) treatment group compared to vehicle group 72 h after ICH (Fig. 4a) . Mice with rhMSP (0.3 lg) treatment showed significantly improved neurological function 72 h after ICH compared to vehicle as demonstrated in modified Garcia test (Fig. 4b, Figure S1 ), corner turn test (Fig. 4c) , and limb placement test (Fig. 4d) .
rhMSP treatment reduced BBB permeability and restored BBB tight junction protein expression after ICH without changing hematoma volume Evans blue dye extravasation assay was evaluated at 24 h after ICH to measure BBB permeability. The extravasation of Evans blue dye was significantly increased in the ipsilateral hemisphere 24 h after ICH compared to sham group (Fig. 5a ). The administration of rhMSP (0.3 lg) significantly reduced extravasation of the dye compared to vehicle group 24 h after ICH.
Hemoglobin assay showed that the hematoma volume was significantly higher in the ICH group compared to sham group 24 h after ICH, and the hematoma volume between vehicle and rhMSP (0.3 lg) treatment groups was not significantly different 24 h after ICH (Fig. 5b) .
Western blot assessment showed that the expression of albumin in the brain samples was significantly increased and the expression of tight junction proteins claudin-5, occludin, and ZO-1 was significantly reduced 24 h after ICH compared to sham group ( Fig. 5c and d) . Treatment with rhMSP (0.3 lg) significantly reduced albumin expression and increased the expression of claudin-5, occludin, and ZO-1 compared to vehicle group 24 h after ICH.
rhMSP increased p-RON/p-GAB1/p-Src/b-catenin after ICH which was abolished with RON and GAB1 siRNA Western blot showed that the expression of p-RON/RON was significantly increased 24 h after ICH with rhMSP (0.3 lg) administration compared to vehicle group, rhMSP treatment combined with RON siRNA but not with scrambled siRNA or GAB1 siRNA reversed this effect ( Fig. 6a and b) . The expression of p-GAB1/GAB1 was significantly increased 24 h after ICH with rhMSP (0.3 lg) administration compared to vehicle animals, while RON siRNA or GAB1 siRNA combined with rhMSP (0.3 lg) treatment significantly reversed this effect but not with scrambled siRNA (Fig. 6a  and c) . rhMSP (0.3 lg) administration also significantly increased the p-Src/Src level compared with vehicle group 24 h after ICH, and this effect was reversed when RON siRNA or GAB1 siRNA was combined with rhMSP (0.3 lg) treatment but not with scrambled siRNA (Fig. 6a and d) . Likewise, the expressions of b-catenin ( Fig. 6a and e) , tight junction proteins claudin-5 ( Fig. 6a and f) , occludin ( Fig. 6a  and g ) and ZO-1 (Fig. 6a and h) were increased with rhMSP (0.3 lg) administration 24 h after ICH compared to vehicle, and these effects were reversed when RON siRNA or GAB1 siRNA was combined with rhMSP (0.3 lg) treatment but not with scrambled siRNA. rhMSP improving neurological function was reversed with RON and GAB1 siRNA Neurobehavior evaluation showed that rhMSP (0.3 lg) administration significantly improved neurological function 24 h after ICH as demonstrated with modified Garcia test and limb placement test compared to vehicle animals ( Fig. 7a and c, respectively) . The improvement in neurological function was reversed in ICH mice that received rhMSP (0.3 lg) treatment combined with RON siRNA or GAB1 siRNA but not scrambled siRNA. The corner turn test did not show significant difference among the rhMSP (0.3 lg) treatment and siRNA groups compared to vehicle group 24 h after ICH (Fig. 7b) . rhMSP promoted nuclear translocation of b-catenin and decreased BBB permeability which was abolished with RON and GAB1 siRNA Western blot was performed 24 h after ICH using cytoplasmic and nuclear fractions from brain samples to investigate the role of b-catenin in BBB protective effects of MSP. There was increase in nuclear b-catenin accumulation and a corresponding decrease in the cytoplasmic fraction with rhMSP (0.3 lg) administration compared to vehicle group 24 h after ICH (Fig. 8a and b respectively) . The administration of RON siRNA or GAB1 siRNA with rhMSP (0.3 lg) treatment reduced b-catenin translocation to the nucleus. Likewise, the expression of albumin was increased in the brain samples 24 h after ICH, which was significantly reduced with rhMSP (0.3 lg) administration compared to vehicle group (Fig. 8c) . This effect was reversed with by RON siRNA and GAB1 siRNA but not scrambled siRNA when combined with rhMSP (0.3 lg) treatment.
rhMSP treatment ameliorated long-term neurofunctional deficits 4 weeks after ICH We chose the Morris water maze to test the effects of rhMSP treatment on spatial learning capacity and memory function recovery 4 weeks after ICH. Vehicle group had significant neurofunctional deficits compared to sham as demonstrated in the test which was evaluated by swim distance (Fig. 9a) , escape latency (Fig. 9b) , probe quadrant duration (Fig. 9c) . However, rhMSP treatment group showed significantly improvement in memory and learning abilities. rhMSP group swam shorter distance to reach the platform (Fig. 9a) and hence a shorter escape latency (Fig. 9b) and they also spent longer duration in the probe quadrant (Fig. 9c) .
Discussion
ICH is an acute neurosurgical disease with high rate of disability and mortality (de Oliveira Manoel et al. 2016) . There have been a number of clinical trials for ICH, but none of the pharmacological and surgical interventions has been approved by food and drug administration for clinical use to manage ICH patients. The mass effect because of compression by the hematoma is a primary factor that leads to neurofunctional deficits after ICH (Keep et al. 2012) . In addition, a series of cascade of events triggered by the hematoma leads to secondary brain injury following ICH (Keep et al. 2012) . Thrombin can induce BBB disruption and aggravate perihematomal cerebral edema (Keep et al. 2012 (Keep et al. , 2014 . Increased permeability of the BBB is a key factor in secondary brain injury after ICH. A large number of studies have confirmed that BBB is an important barrier to the central nervous system (Friedman and Kaufer 2015) . In epilepsy (Noe et al. 2016 ), Alzheimer's disease (Lecler et al. 2017) , schizophrenia (Berman et al. 2016) , stroke (Shi et al. 2017) , and other central nervous system diseases. The intact BBB is a natural barrier between the blood and brain tissues that provides an optimal microenvironment, which is important for the maintenance of neuronal function (Chow and Gu 2015) . Endothelial cells interconnected by tight junctions constitute the core structure of the BBB. Disruption of the tight junction proteins such as occludin, claudin, and ZO-1 compromise the structural integrity of the BBB (Greene and Campbell 2016) . Since BBB disruption plays an important role in secondary brain injury after ICH, preventing the disruption of BBB by stabilizing tight junctions can reduce secondary brain injury after ICH.
Macrophage stimulating protein (MSP) is a HGF. Pro-MSP, a biologically inactive form of MSP, is synthesized by hepatocytes, which is then released into the circulating blood.
Pro-MSP gets enzymatically cleaved and activated to disulfide-linked heterodimer mature MSP (Bezerra et al. 1993; Yoshimura et al. 1993) . Previous studies indicate that tissue injury leads to proteolytic cleavage and activation of pro-MSP to mature MSP, which is the active form that exerts biological effects on different cell types such as keratinocytes, macrophages, and capillaries during wound healing (Yoshimura et al. 1993) . MSP exerts its biological effects by activating receptor tyrosine kinase RON. RON has been shown to play a crucial role in the maintenance of inflammation homeostasis (Wang et al. 2002) . RON is expressed by the microglia, which is the tissue-resident macrophages in the brain (Lee et al. 2004) . Studies have found that MSP interacts with RON to promote tissue repair and suppress inflammation. Additionally, in epithelial cells, RON was shown to be activated by MSP (Gaudino et al. 1994) . In this study, we evaluated the role of MSP and its receptor RON mediated downstream signaling pathway for endothelial protection after ICH.
We evaluated the endogenous expression of MSP and RON after ICH in mice. We found that ICH injury led to a gradual decrease in endogenous expression of MSP from 6 h up to 72 h after ICH. The expression of p-RON/RON also showed a decrease in a time dependent manner starting from 3 h up to 72 h after ICH. These results indicate that MSP and p-RON were gradually consumed after ICH. This decrease in MSP and p-RON may possibly be because of the body's response trying to activate the protective MSP/RON cascade after ICH, in turn leading to its consumption following the injury. We also found that MSP and RON were mostly expressed in endothelial cells, astrocytes and to a lesser extent in neurons evaluated 24 h after ICH. We therefore administered rhMSP to enhance RON activity after ICH. We tested three different doses of rhMSP treatment (0.1, 0.3, and 1.0 lg) in the ICH mouse model. Our results showed that although all three doses significantly reduced brain edema 24 h after ICH, brain edema was reduced to the greatest extent with rhMSP (0.3 lg) dose treatment. This was also reflected in improved neurobehavior function evaluated 24 h after ICH. The ICH mice treated with rhMSP (0.3 lg) showed significant improvement in neurological function 24 h after ICH. We therefore, used dose rhMSP (0.3 lg) for all of the other experiments in this study. The once daily administration of rhMSP (0.3 lg) reduced brain edema and improved neurological function evaluated 72 h after ICH in mice, also ameliorated long-term neurofunctional deficits as assessed by water maze. Since the receptor RON was expressed on endothelial cell, we speculated that RON activation by rhMSP would stabilize the endothelial barrier integrity after ICH. We observed that rhMSP showed protective effects on BBB integrity after ICH, as evidenced by decreased expression of albumin and reduced extravasation of Evans blue dye into the brain parenchyma in ICH mice as well as increased expression of BBB tight junction proteins in ICH mice that received rhMSP. Next, we evaluated the downstream mediator by which MSP activation of RON protects the endothelial junction integrity after ICH. MSP activation of RON leads to dimerization and autophosphorylation of RON, which is essential for RON to initiate the downstream signaling cascades (Gaudino et al. 1994) . Previous study showed that endothelial GAB1 was essential for HGF/c-Met signaling pathway mediated angiogenesis in a mouse model of hind limb ischemia (Shioyama et al. 2011) . GAB1 is a docking protein and the phosphorylation of GAB1 provides binding sites for docking with downstream signal transduction mediators (Shioyama et al. 2011) . Since MSP is an HGFlike protein, we evaluated if GAB1 was involved in the endothelial protective effects of RON activation by MSP. Our results showed that rhMSP administration increased the phosphorylation of RON and GAB1 after ICH in mice, indicating that MSP induced the activation of RON/GAB1. b-catenin is an important mediator in the signaling pathways involved in maintaining the endothelial barrier stability . Previous study found that the expression of nuclear b-catenin in endothelial cells was reduced in hemorrhagic stroke patients (Tran et al. 2016) . Deletion of b-catenin was found to be associated with BBB dysfunction, severe epilepsy, multiple brain petechial hemorrhages, and even death in mice (Tran et al. 2016) . The integrity of the endothelial BBB is primarily controlled by b-catenin mediated transcription of tight junction proteins (He et al. 2015; Tran et al. 2016) . Additionally, b-catenin was shown to be an important downstream target of RON in a study of breast cancer cells (Wagh et al. 2011) . The activation of RON by HGF induced the phosphorylation and nuclear localization of b-catenin (Wagh et al. 2011) . A study on human malignant mesothelioma cells reported the involvement of receptor tyrosine kinases c-Met in the phosphorylation of b-catenin (Qi et al. 2013) . Furthermore, previous studies have reported the involvement of Src kinase dependent phosphorylation of b-catenin in cerebral endothelial cells (Farkas et al. 2005) . Given these evidences, we therefore explored if Src/b-catenin were downstream mediators of RON/GAB1 signaling pathway activated by MSP. Our results showed the rhMSP administration increased the phosphorylation of Src and nuclear localization of b-catenin as well as increased the expression of BBB tight junction proteins. These effects of rhMSP were reversed with the siRNA knockdown of RON or GAB1. After RON AND GAB1 siRNA administration, the expression levels of p-RON, RON, p-GAB1, and GAB1 decreased as seen from our western blot data (Fig. 6) . This helps to verify that the siRNAs successfully knocked-down RON and GAB1 expression levels. These findings indicate that MSP activation of RON induces the phosphorylation of GAB1/Src/b-catenin which possibly stabilized the BBB tight junction proteins after ICH.
In summary, this study indicates that under pathological state such as ICH, the down-regulation of MSP and RON is associated with decreased BBB tight junction proteins. Activating the RON/GAB1/Src/b-catenin signaling pathway with MSP preserved BBB integrity after ICH. Overall, this study provides new insights into the pathological mechanism and treatment measures for BBB disruption after ICH by exploring the MSP/RON/GAB1/Src/b-catenin signaling pathway.
